We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
KISUNLA (Eli Lilly Australia Pty Ltd)
Product name
KISUNLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
223 (255 working days)
Active ingredients
donanemab
Registration type
NCE/ NBE
Indication
KISUNLA is indicated for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and Mild Alzheimer’s dementia (Early Symptomatic Alzheimer’s disease) that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or noncarriers.
Beta amyloid evidence consistent with Alzheimer’s disease (AD) should be confirmed using a validated test prior to initiating treatment.